S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
His system isolated NVIDIA - Here's His Next Buy. (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News

$23.31
+0.08 (+0.34%)
(As of 09/22/2023 ET)
Compare
Today's Range
$22.86
$23.79
50-Day Range
$16.78
$27.80
52-Week Range
$15.50
$34.99
Volume
522,616 shs
Average Volume
554,615 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.17

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
59.4% Upside
$37.17 Price Target
Short Interest
Bearish
21.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.80mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$503,100 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.24) to ($2.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

554th out of 968 stocks

Pharmaceutical Preparations Industry

248th out of 441 stocks


RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Price History

RYTM Stock News Headlines

Rhythm Pharmaceuticals Presents New Data at ESPE 2023
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings
8/01/2023
Today
9/23/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.17
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+59.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-181,120,000.00
Net Margins
-416.41%
Pretax Margin
-416.41%

Debt

Sales & Book Value

Annual Sales
$23.64 million
Book Value
$4.69 per share

Miscellaneous

Free Float
54,228,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
1.62
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. David P. Meeker M.D. (Age 69)
    Chairman, Pres & CEO
    Comp: $1.17M
  • Mr. Hunter C. Smith M.B.A. (Age 54)
    CFO & Treasurer
    Comp: $692.2k
  • Mr. Joseph Shulman (Age 48)
    Chief Technical Officer
    Comp: $608.2k
  • Mr. Yann Mazabraud (Age 50)
    Exec. VP & Head of International
    Comp: $747.43k
  • Ms. Jennifer L. Chien (Age 48)
    Exec. VP & Head of North America
    Comp: $644.2k
  • Mr. Christopher German (Age 52)
    Corp. Controller, Principal Accounting Officer & Exec. Director
  • Mr. David Connolly
    Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty
    Sr. VP & Gen. Counsel
  • Ms. Sarah Ryan
    VP of Sales & Marketing
  • Ms. Pamela J. Cramer (Age 49)
    Chief HR Officer













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RYTM shares.
View RYTM analyst ratings
or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2023?

6 analysts have issued 1-year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $27.00 to $56.00. On average, they predict the company's stock price to reach $37.17 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for RYTM
or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2023?

Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 20.0% and is now trading at $23.31.
View the best growth stocks for 2023 here
.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RYTM earnings forecast
.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Tuesday, August, 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. The firm earned $19.20 million during the quarter, compared to the consensus estimate of $15.03 million. Rhythm Pharmaceuticals had a negative net margin of 416.41% and a negative trailing twelve-month return on equity of 76.93%. The company's revenue was up 111.0% compared to the same quarter last year. During the same period last year, the business earned ($0.89) earnings per share.

What ETFs hold Rhythm Pharmaceuticals' stock?

ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED).

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.01%), RA Capital Management L.P. (9.98%), Goldman Sachs Group Inc. (9.11%), State Street Corp (5.74%), Polar Capital Holdings Plc (3.95%) and VR Adviser LLC (1.92%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud.
View institutional ownership trends
.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $23.31.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.33 billion and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 177 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -